Abstract
The effect of enfuvirtide (ENF) in 11 HIV-1 heavily antiretroviral-experienced children and adolescents enrolled in the HIV-1 Paediatric Spanish cohort was further investigated. Patients who received ENF with novel drugs (etravirine, darunavir, and/or tipranavir) reached and maintained undetectable plasma HIV-1 RNA levels and showed immunological recovery within the first 3 months of therapy that was maintained during the follow-up. Viremia was not fully suppressed in patients who did not combine ENF with novel drugs but interestingly, immunological benefit was observed in half of these patients. Therefore, ENF showed a greater and more stable efficacy when administrated with novel drugs.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adolescent
-
Child
-
Darunavir
-
Drug Resistance, Multiple, Viral
-
Drug Therapy, Combination
-
Enfuvirtide
-
HIV Envelope Protein gp41 / administration & dosage*
-
HIV Envelope Protein gp41 / adverse effects
-
HIV Fusion Inhibitors / administration & dosage*
-
HIV Fusion Inhibitors / adverse effects
-
HIV Infections / drug therapy*
-
HIV Infections / transmission
-
HIV Infections / virology
-
HIV Protease Inhibitors / administration & dosage
-
HIV Protease Inhibitors / adverse effects
-
HIV-1 / drug effects*
-
Humans
-
Infectious Disease Transmission, Vertical
-
Nitriles
-
Peptide Fragments / administration & dosage*
-
Peptide Fragments / adverse effects
-
Pyridazines / administration & dosage
-
Pyridazines / adverse effects
-
Pyridines / administration & dosage
-
Pyridines / adverse effects
-
Pyrimidines
-
Pyrones / administration & dosage
-
Pyrones / adverse effects
-
Sulfonamides / administration & dosage
-
Sulfonamides / adverse effects
-
Time Factors
-
Treatment Outcome
-
Young Adult
Substances
-
HIV Envelope Protein gp41
-
HIV Fusion Inhibitors
-
HIV Protease Inhibitors
-
Nitriles
-
Peptide Fragments
-
Pyridazines
-
Pyridines
-
Pyrimidines
-
Pyrones
-
Sulfonamides
-
etravirine
-
Enfuvirtide
-
Darunavir
-
tipranavir